Blood

Vol. 146, Issue 22 Issue 22 2025
16
Articles

Articles in this Issue

Proteomics: the key to understanding AML hematopoietic aging

Sara J. C. Gosline Nov 27, 2025 pp. 2623-2624 10.1182/blood.2025030883

Death receptor 3 gives life to Tregs in GVHD

Haroon Shaikh Nov 27, 2025 pp. 2626-2627 10.1182/blood.2025030671

<i>FLI1</i> -related thrombocytopenia: piecing together the story

Richard C. Godby, Dong Chen Nov 27, 2025 pp. 2728-2728 10.1182/blood.2025030799

A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease

Anne Chalumeau, Maria Bou Dames, Letizia Fontana et al. Nov 27, 2025 pp. 2641-2655 10.1182/blood.2024028166

Abstract Fetal hemoglobin reactivation is a promising therapy for β-hemoglobinopathies. We developed a prime editing strategy that introduces multiple mutations in the fetal γ-glob...

Above the cut: HbF induction by multiplex prime editing

Carsten W. Lederer Nov 27, 2025 pp. 2619-2620 10.1182/blood.2025031005

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Lorenzo Falchi, Anna Sureda, Sirpa Leppä et al. Nov 27, 2025 pp. 2629-2640 10.1182/blood.2025029909

Abstract Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epco...

Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive <i>KIT</i> p.D816V detection

Paula Navarro-Navarro, María González-Tablas, Alba Pérez-Pons et al. Nov 27, 2025 pp. 2696-2709 10.1182/blood.2025029507

Abstract Detection of KIT p.D816V is a cornerstone in the diagnosis and classification of mast cell activation syndromes (MCAS) and mastocytosis. However, KIT p.D816V may be undete...

Old but gold: ILC-induced T-cell senescence prevents GVHD

Sophia Chen Nov 27, 2025 pp. 2620-2621 10.1182/blood.2025030805

Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT

Duneia McManus, Sabrina N. Copsel, Brent J. Pfeiffer et al. Nov 27, 2025 pp. 2710-2727 10.1182/blood.2025028418

Abstract The current approach to minimize transplant-associated complications, including graft-versus-host disease (GVHD) includes long-term pharmacological immune suppression freq...

MASTering <i>KIT</i> : enhanced sensitivity for refined diagnosis

Yannick Chantran, Michel Arock Nov 27, 2025 pp. 2624-2626 10.1182/blood.2025030940

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Sina A. Beer, David A. Cairns, Charlotte Pawlyn et al. Nov 27, 2025 pp. 2670-2680 10.1182/blood.2025029987

Abstract Functional high-risk (FHR) multiple myeloma (MM) is defined as an unexpected, early relapse (ER) of disease in the absence of baseline molecular or clinical risk factors (...

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. <i>Blood.</i> 2024;144(19):1993-2001.

Nov 27, 2025 pp. 2729-2729 10.1182/blood.2025031951

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Wen-Yan Cheng, Xiao Yi, Zhen-Yi Wang et al. Nov 27, 2025 pp. 2681-2695 10.1182/blood.2024027692

Abstract Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy that increasingly affects the older population, with its posttranscriptional landscape rema...

Better together: epcoritamab boosts R2 in FL

Umberto Vitolo, Francesca Bonello Nov 27, 2025 pp. 2617-2619 10.1182/blood.2025031236

Innate lymphoid cells prevent graft-versus-host disease via IL-9–driven T-cell senescence

Dejene M. Tufa, Eric Hoffmeyer, Kristin L. Schaller et al. Nov 27, 2025 pp. 2656-2669 10.1182/blood.2025028504

Abstract Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that regulate tissue homeostasis and immune responses. How ILCs modulate T cells, remains incompletely underst...

Explain the unexplained

Jill Corre Nov 27, 2025 pp. 2622-2623 10.1182/blood.2025030944

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page